Nosopharm, a biotechnology company specialised in the research and development of new antimicrobial molecules, has announced a financing round of €2.4 million, which will be used to accelerate the regulatory preclinical development of its first antibiotic molecule. Auriga Partners, Kreaxi and Alto Invest join the long-standing shareholders of Nosopharm in this funding round.
The molecule in development, NOSO-95179, targets Enterobacteriaceae — which is a priority pathogen, according to WHO. First-in-man studies are expected to commence in 2019.
“Thanks to this, we now have the funds needed to finalise the preclinical programme for NOSO-95179 and launch additional R&D programmes for anti-infective drugs,” said Philippe Villain-Guillot, president of Nosopharm. “We will submit IND or IMPD applications for NOSO-95179 in 2018, with a view to first-in-man studies in 2019. By the end of 2018, we will also submit a new patent applications covering new therapeutic classes of anti-infectives.”